Rapid quantification of insulin degludec by immunopurification combined with liquid chromatography high-resolution mass spectrometry
Autor
Reverter-Branchat G., Groessl M., Nakas C.T., Prost J.-C., Antwi K., Niederkofler E.E., Bally L.Datum
2020Language
en
Schlagwort
Zusammenfassung
Insulin degludec is an ultra-long-acting insulin analogue that is increasingly being used in diabetes due to its favourable efficacy and safety profile. Thus, there is an increasing demand for a reliable and specific analytical method to quantify insulin degludec for research, pharmaceutical industry and clinical applications. We developed and validated an automated, high-throughput method for quantification of insulin degludec in human blood samples across the expected clinical range combining immunopurification with high-resolution mass spectrometry. Validation was performed according to the requirements of the US Food and Drug Administration. The method satisfyingly met the following parameters: lower limit of quantification (120 pM), linearity, accuracy (error < 5%), precision (CV < 7.7%), selectivity, carry-over, recovery (89.7–97.2%), stability and performance in the presence of other insulin analogues. The method was successfully applied to clinical samples of patients treated with insulin degludec showing a good correlation with the administered dose (r2 = 0.78). High usability of the method is supported by the small specimen volume, automated sample processing and short analysis time. In conclusion, this reliable, easy-to-use and specific mass spectrometric insulin degludec assay offers great promise to address the current unmet need for standardized insulin analytics in academic and industrial research. [Figure not available: see fulltext.]. © 2020, The Author(s).
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Pharmacokinetics of Faster and Standard Insulin Aspart during Fully Closed-Loop Insulin Delivery in Type 2 Diabetes
Herzig D., Dehais J., Prost J.-C., Nakas C.T., Stettler C., Bally L., Hovorka R. (2020)Background: Faster insulin aspart is a novel formulation of insulin aspart aiming to accelerate its subcutaneous absorption. The aim of this study was to compare pharmacokinetics of faster insulin aspart versus standard ... -
Metabolomic, hormonal and physiological responses to hypoglycemia versus euglycemia during exercise in adults with type 1 diabetes
McCarthy O., Pitt J., Churm R., Dunseath G.J., Jones C., Bally L., Nakas C.T., Deere R., Eckstein M.L., Bain S.C., Moser O., Bracken R.M. (2020)Introduction This study sought to compare the metabolomic, hormonal and physiological responses to hypoglycemia versus euglycemia during exercise in adults with type 1 diabetes (T1D). Research design and methods Thirteen ... -
Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement
Lesche D., Sigurdardottir V., Leichtle A.B., Nakas C.T., Christians U., Englberger L., Fiedler M., Largiadèr C.R., Mohacsi P., Sistonen J. (2018)Introduction: The immunosuppressive therapy with everolimus (ERL) after heart transplantation is characterized by a narrow therapeutic window and a substantial variability in dose requirement. Factors explaining this ...